MedWorm: Lymphoma

Myopathy secondary to intravascular large B-cell lymphoma

Neuromuscular Disorders — Fri, 20 Nov 2009 14:37:28 +0100

We report a case of a 78-year-old woman presenting with progressive proximal muscle weakness mainly to lower limbs and myopathic EMG associated with intravascular large B-cell lymphoma.Muscle biopsy showed myopathic changes, intravascular large B-cell lymphoma but no inflammation or fibre necrosis; the patient’s serum cross-reacted with an unidentified nuclear antigen of approximately 45kDa present in muscle and lymphoma cells.Our case illustrates a myopathy associated with intravascular large B-cell lymphoma probably mediated by antibodies cross-reacting with a nuclear protein expressed by neoplastic cells and normal muscle. The nature of this nuclear antigen remains unidentified. (Source: Neuromuscular Disorders)

MedWorm Sponsor Message: The Lymphoma Research Foundation (LRF) is America's largest lymphoma-focused voluntary health organization devoted exclusively to funding lymphoma research and providing patients and health care professionals with critical information on the disease.

Vincristine-Induced Unilateral Ptosis in a Child

Pediatric Neurology — Fri, 20 Nov 2009 14:37:10 +0100

Vincristine is a vinca alkaloid used in combination with other agents in the treatment of solid tumors, lymphoma, and leukemia, as well as for idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia. A dose-limiting complication of vinca alkaloids is neurotoxicity. Vincristine is the oldest and also the most neurotoxic agent in this group. Described here is the case of a 4-year-old girl with unilateral palpebral ptosis. She has been diagnosed with precursor B-cell acute lymphoblastic leukemia. Ptosis was noted on the 45th day of therapy, and the last vincristine was administered on the 28th day of protocol 1. Vincristine-induced unilateral palpebral ptosis is a novel finding. Experience with this case suggests conservative treatment, with periodic examination, especially if pto...

Gemcitabine and vinorelbine therapy for patients with Hodgkin lymphoma

Future Medicine: Pediatric Health — Fri, 20 Nov 2009 12:37:45 +0100

Pediatric Health , December 2009, Vol. 3, No. 6, Pages 525-532. (Source: Future Medicine: Pediatric Health)

Pediatric Hodgkin lymphoma: past, present and future

Future Medicine: Pediatric Health — Fri, 20 Nov 2009 12:37:24 +0100

Pediatric Health , December 2009, Vol. 3, No. 6, Pages 593-606. (Source: Future Medicine: Pediatric Health)

Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic Leukemia

Health News from Medical News Today — Fri, 20 Nov 2009 04:00:00 +0100

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. (Source: Health News from Medical News Today)

Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic Leukemia

Cancer / Oncology News From Medical News Today — Fri, 20 Nov 2009 04:00:00 +0100

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL). (Source: Cancer / Oncology News From Medical News Today)

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

Blood — Thu, 19 Nov 2009 17:02:20 +0100

An important hallmark of cancer progression is the ability of tumor cells to evade immune recognition. Understanding the relationship between neoplastic cells and the immune microenvironment should facilitate the design of improved immunotherapies. Here we identify impaired T-cell immunologic synapse formation as an active immunosuppressive mechanism in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). We found a significant reduction in formation of the F-actin immune synapse in tumor-infiltrating T cells (P < .01) from lymphoma patients compared with age-matched healthy donor cells. Peripheral blood T cells exhibited this defect only in patients with leukemic-phase disease. Moreover, we demonstrate that this T-cell defect is induced after short-term tumor cell contac...

Roles of Radiation Dose and Chemotherapy in the Etiology of Stomach Cancer as a Second Malignancy

International Journal of Radiation Oncology * Biology * Physics — Thu, 19 Nov 2009 15:21:25 +0100

Purpose: To evaluate the roles of radiation dose, chemotherapy, and other factors in the etiology of stomach cancer in long-term survivors of testicular cancer or Hodgkin lymphoma.Methods and Materials: We conducted a cohort study in 5,142 survivors of testicular cancer or Hodgkin lymphoma treated in the Netherlands between 1965 and 1995. In a nested case–control study, detailed information on treatment, smoking, gastrointestinal diseases, and family history was collected for 42 patients with stomach cancer and 126 matched controls. For each subject, the mean radiation dose to the stomach was estimated. Relative risks (RRs) of stomach cancer and the radiation-related excess relative risk (ERR) per gray were calculated by conditional logistic regression analysis.Results: The risk of stoma...

Avascular Necrosis of Bone in Leukemia and Osteonecrosis of Jaw by Bisphosphonates

Journal of Oral and Maxillofacial Surgery — Thu, 19 Nov 2009 14:19:21 +0100

Aseptic osteonecrosis, also known as avascular necrosis of bone or simply osteonecrosis (ON), is a disorder characterized by segmental death of 1 or more osseous sites due to a late toxicity of treatment for childhood leukemia and lymphoma. (Source: Journal of Oral and Maxillofacial Surgery)

Immunomodulatory therapy of cutaneous T-cell lymphoma: A multimodality approach in advanced disease

Journal of the American Academy of Dermatology — Thu, 19 Nov 2009 14:05:32 +0100

Dialogues in Dermatology, a monthly audio program from the American Academy of Dermatology, contains discussions between dermatologists on timely topics. Commentaries from Dialogues Editor-in-Chief Jacqueline M. Junkins-Hopkins, MD, are provided after each discussion as a topic summary and are provided here as a special service to readers of the Journal of the American Academy of Dermatology. (Source: Journal of the American Academy of Dermatology)

Correction

Journal of the American Academy of Dermatology — Thu, 19 Nov 2009 14:05:32 +0100

Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009;60:1001-17. On page 1002 of the article above, the following statement was incorrect: Patients with mild psoriasis have a relative risk of 1.42 and 3.18 of developing Hodgkin's lymphoma and CTCL, respectively. Patients with severe psoriasis have a relative risk of 4.10 and 10.75 of developing Hodgkin's lymphoma and CTCL, respectively. (Source: Journal of the American Academy of Dermatology)

Millennium Initiates First Clinical Trial With The First Oral Proteasome Inhibitor

Health News from Medical News Today — Thu, 19 Nov 2009 14:00:00 +0100

Millennium: The Takeda Oncology Company announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company's second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March. (Source: Health News from Medical News Today)

Millennium Initiates First Clinical Trial With The First Oral Proteasome Inhibitor

Lymphoma / Leukemia News From Medical News Today — Thu, 19 Nov 2009 14:00:00 +0100

Silicone implant and primary breast ALK1-negative anaplastic large cell lymphoma, fact or fiction?

International Journal of Clinical and Experimental Pathology — Thu, 19 Nov 2009 10:38:02 +0100

In this report, we describe an additional case of primary breast ALK1-negative ALCL in the fibrous capsule and cystic fluid of silicone breast implant in a 58 year old woman who underwent breast reconstructive surgery after lumpectomy for her infiltrating breast adenocarcinoma. Morphologically and immunohistochemically, the lymphoma cells may be confused with recurrent infiltrating breast adenocarcinoma or other non-hematolymphoid malignancies. Molecular studies were needed to determine T-lineage differentiation of the malignant lymphoma cells. We will also review the case reports and case series published in the English literature and discuss our current understanding of silicone implant in primary breast ALK1-negative ALCL. PMID: 19918336 [PubMed - in process] (Source: International ...

Persistent non-neoplastic gammadelta-T cells in cerebrospinal fluid of a patient with hepatosplenic (gammadelta) T cell lymphoma: a case report with 6 years of flow cytometry follow-up.

International Journal of Clinical and Experimental Pathology — Thu, 19 Nov 2009 10:38:02 +0100

We describe a case of a 31-year old man diagnosed with a gammadelta HSTCL in 2003, successfully treated with chemotherapy and allogeneic stem cell transplantation, and followed from 2003 to present. Four-color flow cytometry (FC) was performed on a BD FACSCalibur and data analyzed with CellQuest Pro and FCS Express software. For cerebrospinal fluid (CSF), all cells were acquired due to limited material. Cytological correlation was available on all specimens. Molecular studies for T-cell gene rearrangement were non-contributory. By FC, the diagnostic HSTCL immunophenotype was CD3 (+), CD7 (+), CD2 (+), CD5 (-), CD4 (-), CD8 (-), TCR gammadelta (+). Subsequent CSF FC analysis revealed a distinct population of gammadelta T-cells in all specimens, ranging from <1% to 13% of lymphocytes. Con...

Pitfalls in diagnostic hematopathology - Part II.

International Journal of Clinical and Experimental Pathology — Thu, 19 Nov 2009 10:38:02 +0100

Authors: Zhao XF The overlapping features of malignant lymphomas create a diagnostic "grey zone" , and lead to the invention of "grey zone lymphomas". There are several major grey zone lymphomas: 1) Lymphomas with overlapping features of Hodgkin lymphoma and large B-cell lymphoma; 2) Lymphomas with overlapping features of Burkitt lymphoma and diffuse large B-cell lymphoma; 3) Lymphomas with overlapping features of nodular lymphocyte predominant Hodgkin lymphoma and T-cell/histiocyte rich large B-cell lymphoma; 4) Lymphomas with overlapping features of Hodgkin lymphoma, anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphoma (PTCL); 5) T-cell classical Hodgkin lymphoma and ALCL-HL. The second review of this series will be dedicated to discussion of the "grey zone" features ...

[Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long-term follow-up results.]

Orvosi Hetilap — Thu, 19 Nov 2009 00:00:00 +0100

Conclusion: Our results, in accordance with literature, clearly indicate that patients with negative FDG-PET results are unlikely to progress or relapse during a long follow-up. However, false positive uptake is a problem. We have investigated the effect of age, histological subtype, clinical stage and the type of treatment on the accuracy, but on the basis of these facts we could not find any significant difference. However, the date of the investigation influenced the results: before 2000 the number of false results was significantly higher than after that time, which shows the importance of investigators' experience. PMID: 19910278 [PubMed - in process] (Source: Orvosi Hetilap)

Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides

Journal of the European Academy of Dermatology and Venereology — Thu, 19 Nov 2009 00:00:00 +0100

Conclusions Our results confirm that phototherapy is a safe, effective and well-tolerated, first-line therapy in patients with early-stage cutaneous T-cell lymphoma, with prolonged disease-free remissions being achieved. It suggests that narrowband UVB is at least as effective as PUVA for treatment of early-stage MF. (Source: Journal of the European Academy of Dermatology and Venereology)

Society for Hematology and Stem Cells Travel Grants to ISEH 2010 Meeting

ScanGrants feed — Thu, 19 Nov 2009 00:00:00 +0100

Date: 15 - 18 September, 2010Location: Melbourne Convention & Exhibition Centre, Melbourne Australia (www.mcec.com.au/) Through the generous support of the State government of Victoria we are able to offer up to 200 travel grants for PhD students and post-doctoral delegates as follows:Delegates traveling from Europe AUD$2000Delegates traveling from the USA AUD$1500Delegates traveling from Asia AUD$1200Delegates traveling from New Zealand or within Australia AUD$300Applications need to be submitted with your abstract and will be assessed based on the abstract rankings. Travel award applicants must also include a letter from their Mentor/Supervisor with their abstract submission requesting travel suppor...

CXCL12 rs1801157 polymorphism in patients with breast cancer, hodgkin's lymphoma, and non-hodgkin's lymphoma

Journal of Clinical Laboratory Analysis — Thu, 19 Nov 2009 00:00:00 +0100

Chemokines and their receptors regulate the trafficking of immune cells during their development, inflammation, and tissue repair. The single-nucleotide polymorphism (SNP) rs1801157 (previously known as CXCL12-A/ stromal cell-derived factor-1 (SDF1)-3[prime]A) in CXCL12/SDF1 gene was assessed in breast cancer, Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL), since the chemokine CXCL12, previously known as SDF1, and its receptor CXCR4 regulate leukocyte trafficking and many essential biological processes, including tumor growth, angiogenesis, and metastasis of different types of tumors. Genotyping was performed by PCR-RFLP (polymerase chain reaction followed by restriction fragment length polymorphism) using a restriction enzyme HpaII cleavage. No significant difference was observ...

Immuno-Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study [Hematologic Malignancies]

Journal of Clinical Oncology — Wed, 18 Nov 2009 23:02:36 +0100

Conclusion Our study demonstrates that combining immunohistochemistry with FISH allows construction of an immunoFISH index that significantly predicts survival in elderly DLBCL patients treated with R-CHOP. (Source: Journal of Clinical Oncology)

Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211 [Hematologic Malignancies]

Journal of Clinical Oncology — Wed, 18 Nov 2009 23:02:36 +0100

Conclusion Concurrent chemoradiotherapy using multidrug resistance-nonrelated agents and etoposide is a safe and effective treatment for localized nasal NK/T-cell lymphoma and warrants further investigation. (Source: Journal of Clinical Oncology)

TRACO: Lymphoma and Immunology

Videocast - All Events — Wed, 18 Nov 2009 18:59:00 +0100

Presented by: W. Wilson and P. HenkartCategory: TRACOAired date: 11/16/2009 (Source: Videocast - All Events)

Extracorporeal photo-apheresis for the treatment of steroid-resistant graft versus host disease

Transfusion and Apheresis Science — Wed, 18 Nov 2009 14:25:08 +0100

Abstract: Acute and chronic graft versus host disease are frequent and potentially severe complications of allogeneic hematopoietic stem cell transplantation and are among the leading causes of non-relapse transplant-related mortality. For patients with steroid refractory disease, prognosis is particularly poor and although a variety of treatment options are available, responses are commonly transient and the side effects often intolerable. Since it was first introduced for the treatment of cutaneous T-cell lymphoma, extracorporeal photo-apheresis has been utilized as an immunomodulatory therapy for certain autoimmune diseases and solid organ transplant rejection. Recently, extracorporeal photo-apheresis has become a promising alternative for patients with graft versus host disease with di...

Seattle Genetics Initiates Phase I Clinical Trial Of Antibody-Drug Conjugate SGN-75

Health News from Medical News Today — Wed, 18 Nov 2009 08:00:00 +0100

Seattle Genetics, Inc. (Nasdaq: SGEN) announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company's proprietary technology. (Source: Health News from Medical News Today)

Seattle Genetics Initiates Phase I Clinical Trial Of Antibody-Drug Conjugate SGN-75

Cancer / Oncology News From Medical News Today — Wed, 18 Nov 2009 08:00:00 +0100

Suzanne Somers speaks out against the conventional cancer industry: mammograms, chemotherapy vs. alternative cures

NaturalNews.com — Wed, 18 Nov 2009 07:00:00 +0100

(NaturalNews) As the author of the New York Times bestseller, "Knockout: Interviews with doctors who are curing cancer," Suzanne Somers is making waves across the cancer industry. Her powerful, inspired message of informed hope is reaching millions of readers who are learning about the many safe, effective options for treating cancer that exist outside the realm of the conventional cancer industry (chemotherapy, surgery and radiation).Recently, Suzanne Somers spoke with NaturalNews editor Mike Adams, the Health Ranger, to share the inspiration for her new book Knockout. "People are just starving for some new information... for other options, for hope in [treating] cancer," she explained.The full interview with Suzanne Somers is available as a downloadable MP3 file from NaturalNews.com: htt...

Plasmacytoid lymphoma treated with rituximab as first-line monotherapy

Clinical and Translational Oncology — Wed, 18 Nov 2009 04:58:56 +0100

Content Type Journal ArticleCategory CorrespondenceDOI 10.1007/s12094-009-0429-4Authors I. Blancas López-Barajas, Hospital Clínico San Cecilio de Granada Unidad de Oncología Avda. Dr. Olóriz, 16 ES-18012 Granada SpainIrene Zarcos, Hospital Clínico San Cecilio de Granada Unidad de Oncología Avda. Dr. Olóriz, 16 ES-18012 Granada SpainFrancisco J. Gómez, Facultad de Medicina de Granada Departamento de Medicina Granada SpainMaría Teresa Delgado, Hospital Clínico San Cecilio de Granada Unidad de Oncología Avda. Dr. Olóriz, 16 ES-18012 Granada SpainJosefa Carrillo, Hospital Clínico San Cecilio de Granada Unidad de Oncología Avda. Dr. Olóriz, 16 ES-18012 Granada SpainMarta Legerén, Hospital Clínico San Cecilio de Granada Unidad de Oncología Avda. Dr. Olóriz, 16 ES-18012 Gra...

Primary central nervous system lymphoma: Immunohistochemical profile and prognostic significance

Neuropathology — Wed, 18 Nov 2009 00:00:00 +0100

Primary central nervous system lymphoma (PCNSL) is a rare subtype of non-Hodgkin lymphoma (NHL) with extranodal location affecting only the CNS, meninges and eye, without visceral or lymph node involvement. Its incidence has increased sharply over the past three decades, especially in immunocompetent subjects. Most PCNSL cases are diffuse large B-cell lymphomas (DLBCLs). However, it differs from nodal DLBCL in that it has a worse prognosis. DLBCLs are a heterogeneous entity and according to new genomic discoveries, classifications into prognostic subgroups have been embarked upon. Two prognostic algorithms were then prepared using a panel of immunohistochemical markers (CD10, Bcl6, MUM1/IRF-4, and Bcl2), thus categorizing DLBCL into two subgroups, GCB (germinal centre B-cell-like) or non-G...

Borderline CD30+ cutaneous lymphoproliferative disorder: report of a case with expression of cytotoxic markers and response to clarithromycin

Journal of Cutaneous Pathology — Wed, 18 Nov 2009 00:00:00 +0100

We describe a case of borderline CD30+ CLPD with cytotoxic phenotype, presenting in a 22-year-old male patient as an ulcer on the forearm. He reported having had similar ulcers on the buttock and thigh that spontaneously regressed over the course of 1 year. The lesion resolved with a single course of clarithromycin; a subsequent lesion, too, responded to clarithromycin, and no recurrences or systemic involvement have been documented in the 9-month follow-up. A conservative approach in the management of CD30+ CLPD is recommended. We believe that the anti-inflammatory and apoptotic effects of clarithromycin on T cells may have hastened the remission process. Ponte P, Serrão V, Viana I, Vale E, João A, Cerroni L. Borderline CD30+ cutaneous lymphoproliferative disorder: report of a case with...

IBD Drugs and Cancer Risk [The World in Medicine]

JAMA — Tue, 17 Nov 2009 20:51:28 +0100

(Source: JAMA)

Diagnosis of childhood cancer.

Primary Care — Tue, 17 Nov 2009 16:16:33 +0100

Authors: Raab CP, Gartner JC Childhood cancer is uncommon but remains the leading cause of disease-related death in children. Symptoms are often vague or insidious; they may suggest a more common alternative diagnosis, and they are quite different from those associated with adult malignancy. The skilled office practitioner must consider cancer as a diagnosis when symptoms/signs persist or when multiple symptoms point toward a possible diagnosis of malignancy. Early diagnosis is critical, as survival rates have increased dramatically over the past decades. Prolonged delay in diagnosis is common, especially for brain tumors and certain lymphomas (Hodgkin disease). When one encounters symptoms suspicious for a childhood malignancy, it is imperative that the child be referred to a pediatri...

Survivorship: adult cancer survivors.

Primary Care — Tue, 17 Nov 2009 16:16:23 +0100

Authors: Ganz PA During the next decade, a rapid increase in the number of new cancer diagnoses in the population as well as a growing number of cancer survivors can be expected. Cancer is anticipated to exceed cardiovascular disease as the primary cause of mortality in the United States population. Despite efforts in tobacco control, the aging of the population and obesity epidemic will contribute toward the increasing incidence of cancer. Although oncology specialists will continue to play a critical role in the diagnosis and initial treatment of patients with cancer, primary care providers will need to play an expanding role in the early detection of cancer, as well as the follow-up, health promotion, and cancer surveillance that will be necessary after initial cancer treatment. Onc...

Plasma HIV RNA is a Risk Factor for Non-Hodgkin's Lymphoma

Medscape Today Headlines — Tue, 17 Nov 2009 15:51:51 +0100

John G. Bartlett, MD, comments on this observational study that establishes viral load as a risk factor for non-Hodgkin's lymphoma in people living with HIV/AIDS. Medscape HIV/AIDS (Source: Medscape Today Headlines)

How Cells Tolerate DNA Damage - MDC Researchers Identify Start Signal For Cell Survival Program

Health News from Medical News Today — Tue, 17 Nov 2009 13:00:00 +0100

Cancer researchers of the Max DelbrÃ¼ck Center for Molecular Medicine (MDC) Berlin-Buch have gained new insights into how cells react to DNA damage. Dr. Michael Stilmann, Dr. Michael Hinz and Professor Claus Scheidereit have shown that the protein PARP-1, which detects DNA damage within seconds, activates the transcription factor NF-kappaB, a well-known regulator of gene expression. (Source: Health News from Medical News Today)

How Cells Tolerate DNA Damage - MDC Researchers Identify Start Signal For Cell Survival Program

Lymphoma / Leukemia News From Medical News Today — Tue, 17 Nov 2009 13:00:00 +0100

Co-Founder Of Microsoft Diagnosed With Non-Hodgkin's Lymphoma

Lymphoma / Leukemia News From Medical News Today — Tue, 17 Nov 2009 11:00:00 +0100

Paul Allen who co-founded the computer giant Microsoft with Bill Gates in the 1970s has been diagnosed with Non-Hodgkin's Lymphoma, 25 years after surviving Hodgkin's lymphoma. The news was announced in a memo to the staff of Allen's company Vulcan, by CEO Jody Allen, who is also Paul Allen's sister. A copy of the memo was also sent to the media. (Source: Lymphoma / Leukemia News From Medical News Today)

Co-Founder Of Microsoft Diagnosed With Non-Hodgkin's Lymphoma

Health News from Medical News Today — Tue, 17 Nov 2009 11:00:00 +0100

EntreMed's ENMD-2076 Active In Solid And Hematological Cancers

Health News from Medical News Today — Tue, 17 Nov 2009 09:00:00 +0100

EntreMed, Inc. ( ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer announced the presentation of data for the Phase 1 study for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, in leukemia patients. The Company also announced that it has selected ovarian cancer as an initial Phase 2 indication. (Source: Health News from Medical News Today)

EntreMed's ENMD-2076 Active In Solid And Hematological Cancers

Lymphoma / Leukemia News From Medical News Today — Tue, 17 Nov 2009 09:00:00 +0100

Microsoft co-founder Allen diagnosed with cancer

CNN.com - Health — Tue, 17 Nov 2009 03:09:05 +0100

Microsoft co-founder Paul Allen has been diagnosed with non-Hodgkin's lymphoma, more than 25 years after he was treated for Hodgkin's disease, a spokesman at his company Vulcan Inc. told CNN on Monday. (Source: CNN.com - Health)

Associations between leisure-time physical activity and health-related quality of life among adolescent and adult survivors of childhood cancers

Psycho-Oncology — Tue, 17 Nov 2009 00:00:00 +0100

Objective: Survivors of childhood cancer are at an increased risk for reduced quality of life (QOL), yet few studies have explored factors associated with improving health-related QOL (HRQOL) in this population. We thus explored the relationship between physical activity (PA) and HRQOL among survivors of childhood cancer.Methods: A total of 215 survivors of childhood lymphoma, leukemia, and central nervous system cancers completed mailed surveys that elicited information regarding leisure-time PA (LTPA) measured in metabolic equivalents, HRQOL, and diagnostic and demographic factors. Correlations and adjusted regression models were used to explore the relationship between LTPA and HRQOL.Results: In the total sample, modest, yet significant linear associations were observed between LTPA and...

Primary Nasopharyngeal non-Hodgkin lymphomas: a retrospective review of 26 Moroccan patients.

BMC Ear, Nose and Throat Disorders — Tue, 17 Nov 2009 00:00:00 +0100

Conclusion: From our study, we conclude that histological characteristics, principle of treatment and outcome of primary NNHL patients are particular and more studies have to be directed . (Source: BMC Ear, Nose and Throat Disorders)

Phosphorylation regulates human T-cell leukemia virus type 1 Rex function

Retrovirology — Tue, 17 Nov 2009 00:00:00 +0100

Conclusion: We have mapped completely the site-specific phosphorylation of Rex-1 identifying a total of seven residues; Thr-22, Ser-36, Thr-37, Ser-70, Ser-97, Ser-106, and Thr-174. Overall, this work is the first to completely map the phosphorylation sites in Rex-1 and provides important insight into the regulation of Rex-1 function. (Source: Retrovirology)

Leukonychia Related to Vorinostat [Correspondence]

Archives of Dermatology — Mon, 16 Nov 2009 20:51:45 +0100

(Source: Archives of Dermatology)

Randomized Clinical Trials in Gastrointestinal Stromal Tumors

Surgical Oncology Clinics of North America — Mon, 16 Nov 2009 15:37:48 +0100

This article provides a summary of recent randomized clinical trials of these tumors. (Source: Surgical Oncology Clinics of North America)

Anaplastic large cell lymphoma: another entity in the differential diagnosis of small round blue cell tumors

Annals of Diagnostic Pathology — Mon, 16 Nov 2009 15:08:38 +0100

Abstract: We saw in consultation a biopsy specimen from a 6-year old girl with anaplastic lymphoma kinase (ALK)–positive anaplastic large cell lymphoma (ALCL). The tumor arose in soft tissue of the neck, and diagnostic tissue was obtained by core needle biopsy. Histologically, the neoplasm was cellular without pattern. Immunohistochemical workup with a large panel of antibodies at another institution showed immunoreactivity for NB84 and neuron specific enolase (dim). Antibodies specific for CD3, CD20, and CD45/LCA were negative; CD30 or ALK were not assessed. Electron microscopy showed cytoplasmic structures thought to be neurosecretory granules. The neoplasm was interpreted initially as a neuroblastoma. At the time of our review, we considered the possibility of ALCL. Immunohistochemica...

A Call to Action for Hematology Fellows: Clinical Advances and Patient Considerations in Lymphomas

Clinical Care Options Oncology - Lymphoma — Mon, 16 Nov 2009 14:11:01 +0100

Learning Module - Alissa Marr, MD, and James O. Armitage, MD, provide an overview of non-Hodgkin’s lymphoma for oncology/hematology fellows. (Source: Clinical Care Options Oncology - Lymphoma)

FDA fast tracks Rx for hard-to-treat peripheral T-cell lymphoma

Cancer Network — Mon, 16 Nov 2009 12:00:00 +0100

Allos Therapeutics has received accelerated FDA approval for Folotyn (pralatrexate) as a single-agent treatment in patients with relapsed or refractory peripheral T-cell lymphoma. (Source: Cancer Network)

Elitek FDA-approved for recombinant uricolytic agent for tumor lysis

Cancer Network — Mon, 16 Nov 2009 12:00:00 +0100

Rasburicase (Elitek) has been granted FDA approval for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies. (Source: Cancer Network)

Finding May Give Hope To More Leukemia Patients So They May Live Cancer-Free

Health News from Medical News Today — Mon, 16 Nov 2009 08:00:00 +0100

Finding May Give Hope To More Leukemia Patients So They May Live Cancer-Free

Lymphoma / Leukemia News From Medical News Today — Mon, 16 Nov 2009 08:00:00 +0100

A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning. This finding has the potential to change the current medical practice of using one unit of UCB for treatment of patients who are at high risk for recurrence of leukemia and other cancers of the blood and bone marrow. Michael Verneris, M.D. (Source: Lymphoma / Leukemia News From Medical News Today)

Therapeutic Approaches in Non-Hodgkin’s Lymphoma: A Case Review

Clinical Care Options Oncology - Lymphoma — Mon, 16 Nov 2009 00:00:00 +0100

CCO Slideset - Review a case-based analysis of optimal management strategies for non-Hodgkin’s lymphoma with an emphasis on diagnosis, prognostic assessment, and treatment. (Source: Clinical Care Options Oncology - Lymphoma)

Therapeutic Approaches in Non-Hodgkin’s Lymphoma: A Case Review

Clinical Care Options Oncology - Lymphoma — Mon, 16 Nov 2009 00:00:00 +0100

CCO Virtual Presentation - James O. Armitage, MD, and Alissa Marr, MD, provide a case-based analysis of optimal management strategies for non-Hodgkin’s lymphoma with an emphasis on diagnosis, prognostic assessment, and treatment. (Source: Clinical Care Options Oncology - Lymphoma)

Fludarabine, Bortezomib, Myocet® and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma

British Journal of Haematology — Mon, 16 Nov 2009 00:00:00 +0100

(Source: British Journal of Haematology)

Favourable outcome of pneumonia due to novel influenza A/H1N1 2009 virus in a splenectomised adult patient undergoing therapy for non-Hodgkin lymphoma

British Journal of Haematology — Mon, 16 Nov 2009 00:00:00 +0100

(Source: British Journal of Haematology)

Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma

BMC Medical Genetics - Latest articles — Mon, 16 Nov 2009 00:00:00 +0100

Conclusion: These results suggest an influence of RAD50 and NBS1 on susceptibility to diffuse large B-cell lymphoma and marginal zone lymphoma. Larger association and functional studies could confirm such a role. (Source: BMC Medical Genetics - Latest articles)

Goldhirsh Foundation 2010 Grant Cycle of the Brain Tumor Research Awards Program

ScanGrants feed — Sun, 15 Nov 2009 00:00:00 +0100

The Goldhirsh Foundation is pleased to announce the 2010 Grant Cycle of the Brain Tumor Research Awards Program. The next application deadline is Thursday, January 7, 2010, 12:00 Noon, U.S. and Canada Eastern Time (GMT-5) for awards beginning on July 1, 2010. The Goldhirsh Foundation was established by Bernard A. Goldhirsh in 2000, shortly after he was diagnosed with brain cancer. Since his death in 2003, the Board of Directors of the Foundation (which includes his two children) has been shaping a grantmaking program that reflects his values and entrepreneurial spirit. We are dedicated to making a difference in the lives of people touched by the organizations and projects we support.A significant portion of the Foundation’s annual grantmaking is devoted to support for brain tumor re...

Primary cardiac T-cell lymphoma in a child

European Heart Journal — Sat, 14 Nov 2009 08:06:29 +0100

(Source: European Heart Journal)

Artificial Sweeteners are Continually Found to be Unsafe and Toxic

NaturalNews.com — Sat, 14 Nov 2009 07:00:00 +0100

(NaturalNews) A recent study presented at the annual meeting of the American Society of Nephrology in San Diego found that adult women who drink at least two diet sodas a day experience a 30 percent drop in kidney function over the course of a decade. Findings indicate that artificial sweeteners such as aspartame and sucralose are the culprits in the rapid degeneration of glomerular filtration rates in the kidneys of those consuming excessive amounts of artificially-sweetened diet sodas.Dr. Julie Lin of Brigham and Women's Hospital in Boston and her colleague Dr. Gary Curhan conducted the research correlating artificial sweetener intake to kidney degradation, highlighting one of the many dangers of artificial sweeteners.A 2005 study conducted by Dr. Morando Soffritti of the esteemed Europe...

'Brothers and Sisters': Misguided cancer treatment plan

L.A. Times - Health — Sat, 14 Nov 2009 03:04:31 +0100

Kitty Walker (Calista Flockhart) is thinking of turning to flaxseed oil and herbs to cure her non-Hodgkin's lymphoma. Kitty Walker (Calista Flockhart) s thinking of turning to flaxseed oil and herbs to cure her non-Hodgkin's lymphoma. (Source: L.A. Times - Health)

'Brothers and Sisters': Will alternative cancer treatments work?

L.A. Times - Health — Sat, 14 Nov 2009 02:04:38 +0100

Kitty Walker (Calista Flockhart) is thinking of turning to flaxseed oil and herbs to cure her non-Hodgkin's lymphoma, but is that a smart choice in the real world? 'Brothers and Sisters' ABC, Sunday, Nov. 8, 10 p.m. (Source: L.A. Times - Health)

Central nervous system T-cell lymphoma in acquired immunodeficiency syndrome

British Journal of Haematology — Sat, 14 Nov 2009 00:00:00 +0100

(Source: British Journal of Haematology)

Approved Lymphoma Drug Shows Promise In Early Tests Against Bone Cancer

Cancercompass News: Other Cancer — Sat, 14 Nov 2009 00:00:00 +0100

A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. (Source: Cancercompass News: Other Cancer)

A high throughput experimental approach to identify miRNA targets in human cells

Nucleic Acids Research — Fri, 13 Nov 2009 14:41:14 +0100

In conclusion, we report a method which can establish the miRNA-targetome in untreated human cells and identify miRNA specific targets in a high throughput manner. This approach is applicable to identify miRNA targets in any human tissue sample or purified cell population in an unbiased and physiologically relevant manner. (Source: Nucleic Acids Research)

Safety Profile of IBD: Lymphoma Risks

Gastroenterology Clinics of North America — Fri, 13 Nov 2009 14:14:16 +0100

This article describes the cancer risks of commonly used inflammatory bowel disease (IBD) medications, with an emphasis on hematologic malignancy risks. The increasing use of immunosuppressant therapies in the treatment of IBD has raised this question to an even greater importance. Studies evaluating these medications are complicated due to varying disease severity and concomitant use of other immunosuppressant medication. The potential risks of all therapies must be weighed against the benefits these therapies can offer these patients. (Source: Gastroenterology Clinics of North America)

Mistletoe therapy as a therapeutic option in a child with lymphomatoid papulosis/CD 30-positive cutaneous lymphoproliferative papulosis

European Journal of Integrative Medicine — Fri, 13 Nov 2009 13:55:37 +0100

In conclusion we present a patient with a rare skin disease (LP) with lymph node involvement who is successful treated with mistletoe as a new promising therapeutic option for patients with lymphomatoid papulosis. Further studies should be initiated. (Source: European Journal of Integrative Medicine)

Life quality and subjective feeling with additional homeopathic treatment in cancer patients

European Journal of Integrative Medicine — Fri, 13 Nov 2009 13:55:29 +0100

Conclusion: In summary, homeopathy was well accepted by the investigated patients. Improvement in QoL as well as in subjective existential orientation warrants further investigations. Oncologists may want to receive information about the use of homeopathy and other forms of complementary medicine in patients undergoing treatment for cancer. (Source: European Journal of Integrative Medicine)

Sonic Hedgehog Signaling Proteins and ATP-Binding Cassette G2 Are Aberrantly Expressed in Diffuse Large B-Cell Lymphoma

Medscape Hematology-Oncology Headlines — Fri, 13 Nov 2009 13:40:00 +0100

How does the expression of sonic hedgehog signaling proteins compare among diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia? Modern Pathology (Source: Medscape Hematology-Oncology Headlines)

A case of primary cutaneous B cell lymphoma of the knee.

Dermatol Online J — Fri, 13 Nov 2009 12:06:04 +0100

We report the case of a gentleman with a primary cutaneous B cell lymphoma of the leg who underwent an amputation and later died. This is an uncommon type of cutaneous lymphoma with poor prognosis and the case demonstrates how aggressive the tumor can become. PMID: 19903434 [PubMed - in process] (Source: Dermatol Online J)

Diffuse large B-cell lymphoma presenting as piriformis syndrome

Muscle and Nerve — Fri, 13 Nov 2009 00:00:00 +0100

Piriformis syndrome (PS) is a rare condition characterized by pain and paresthesia of the buttock, often radiating to the posterior thigh. A patient with sciatica that was clinically suspicious for PS, underwent diagnostic work-up. A diagnosis of diffuse large B-cell lymphoma with neurolymphomatosis (NL) was made. To our knowledge, this is the first report of NL presenting as PS. NL is a possible cause of secondary PS. Muscle Nerve, 2010 (Source: Muscle and Nerve)

Hypermethylation of the DLC1 CpG island does not alter gene expression in canine lymphoma

BMC Genetics - Latest articles — Fri, 13 Nov 2009 00:00:00 +0100

Conclusions: The canine DLC1 is constructed highly similarly to the human gene, which has been shown to be an important tumor suppressor in many forms of cancer. As in human NHL, the promoter CpG island of DLC1 in canine NHL samples is abnormally hypermethylated, relative to normal lymphoid tissue. This study confirms that hypermethylation occurs in canine cancers, further supporting the use of companion dogs as comparative models of disease for evaluation of carcinogenesis, biomarker diagnosis, and therapy. (Source: BMC Genetics - Latest articles)

Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?

Ann Oncol — Fri, 13 Nov 2009 00:00:00 +0100

CONCLUSIONS: Asymptomatic patients without morphological residues and an early stage of disease do not need a routine FDG-PET/CT for follow-up. Asymptomatic patients with morphological residues should receive routine follow-up FDG-PET/CT for the first 24 months. Only patients with advanced initial stage do need a routine follow-up FDG-PET/CT beyond 24 months. PMID: 19914963 [PubMed - as supplied by publisher] (Source: Ann Oncol)

Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

Ann Oncol — Fri, 13 Nov 2009 00:00:00 +0100

CONCLUSION: The C5R protocol was feasible in the multicentric setting with favorable long-term survival in patients younger than 60 years. Despite dose adaptation, results in older patients were disappointing. PMID: 19914958 [PubMed - as supplied by publisher] (Source: Ann Oncol)

FDA Approves New Drug For Rare Cancer Cutaneous T-Cell Lymphoma

Health News from Medical News Today — Thu, 12 Nov 2009 19:00:00 +0100

The US Food and Drug Administration (FDA) has approved a new drug for treating patients with the rare white blood cell cancer Cutaneous T-cell Lymphoma (CTCL); the drug Istodax (romidepsin) is injectable and is marketed by Gloucester Pharmaceuticals Inc of Cambridge, Massachusetts. Every year, about 1,500 Americans are newly diagnosed with CTCL, a type of non-Hodgkin's lymphoma. (Source: Health News from Medical News Today)

FDA Approves New Drug For Rare Cancer Cutaneous T-Cell Lymphoma

Cancer / Oncology News From Medical News Today — Thu, 12 Nov 2009 19:00:00 +0100

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment

Annals of the Rheumatic Diseases — Thu, 12 Nov 2009 18:02:11 +0100

Conclusions: The IR of total malignancy (excluding NMSC), breast, colorectal, lung cancers and lymphoma in the abatacept CDP were consistent with those in a comparable RA population. These data suggest no new safety signals with respect to malignancies, which will continue to be monitored. (Source: Annals of the Rheumatic Diseases)

Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease

Blood — Thu, 12 Nov 2009 17:38:06 +0100

Acute graft-versus-host disease (aGVHD) often precludes successful immunotherapy of hematologic malignancies with allogeneic T cells. Therefore, we investigated the effect of immunomodulatory superagonistic anti-CD28 monoclonal antibodies (CD28-SA) on the capacity of allogeneic T cells to mediate both aGVHD and the protective graft-versus-tumor (GVT) response. In vivo pretreatment of donor C57BL/6 mice or short-term in vitro culture of donor lymph node cells with a CD28-SA efficiently protected BALB/c recipient mice from aGVHD. This protection strongly relied on the presence of CD28-SA–activated CD4+ CD25+ Foxp3+ regulatory T cells in the donor T-cell inoculum. With respect to the GVT response, CD28-SA–prestimulated T cells were still as potent in clearing lymphoma cells as wer...

Allogeneic transplantation for children and adolescents with Hodgkin lymphoma

Blood — Thu, 12 Nov 2009 17:38:06 +0100

(Source: Blood)

Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees

Blood — Thu, 12 Nov 2009 17:38:05 +0100

We investigated the ability of CpG-oligodeoxynucleotide to generate an anti-tumor CD8+ T-cell immune response and to synergize with passive antibody therapy. For these studies, we generated an antibody against the idiotype on the A20 B-cell lymphoma line. This antibody caused the regression of established tumors, but ultimately the tumors relapsed. The escaping surface IgG-negative tumor cells were resistant to both antibody-dependent cellular cytotoxicity and signaling-induced cell death. Addition of intratumoral CpG to antibody therapy cured large established tumors and prevented the occurrence of tumor escapees. The failure of the combination therapy in mice deficient for CD8+ T cells demonstrates the critical role of CD8+ T cells in tumor eradication. When mice were inoculated with 2 t...

Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities

Blood — Thu, 12 Nov 2009 17:38:05 +0100

STATs are constitutively activated in several malignancies. In primary mediastinal large B-cell lymphoma and Hodgkin lymphoma (HL), inactivating mutations in SOCS1, an inhibitor of JAK/STAT signaling, contribute to deregulated STAT activity. Based on indications that the SOCS1 mutations are caused by the B cell–specific somatic hypermutation (SHM) process, we analyzed B-cell non-HL and normal B cells for mutations in SOCS1. One-fourth of diffuse large B-cell lymphoma and follicular lymphomas carried SOCS1 mutations, which were preferentially targeted to SHM hotspot motifs and frequently obviously inactivating. Rare mutations were observed in Burkitt lymphoma, plasmacytoma, and mantle cell lymphoma but not in tumors of a non–B-cell origin. Mutations in single-sorted germinal cen...

How I treat mycosis fungoides and Sezary syndrome

Blood — Thu, 12 Nov 2009 17:38:04 +0100

The most common subtypes of primary cutaneous T-cell lymphomas are mycosis fungoides (MF) and Sézary syndrome (SS). The majority of patients have indolent disease; and given the incurable nature of MF/SS, management should focus on improving symptoms and cosmesis while limiting toxicity. Management of MF/SS should use a "stage-based" approach; treatment of early-stage disease (IA-IIA) typically involves skin directed therapies that include topical corticosteroids, phototherapy (psoralen plus ultraviolet A radiation or ultraviolet B radiation), topical chemotherapy, topical or systemic bexarotene, and radiotherapy. Systemic approaches are used for recalcitrant early-stage disease, advanced-stage disease (IIB-IV), and transformed disease and include retinoids, such as bexarotene, inte...

Experimental protein for leukaemia

NHS News Feed — Thu, 12 Nov 2009 17:09:00 +0100

Conclusion This study has developed a new method for targeting the NOTCH1 transcription factor. The technique may eventually lead to the development of new drugs for T-ALL and other Notch-related conditions. However, this will be a long-term goal as much more animal and human research will be needed to determine the effectiveness and safety of this new approach. Links To The Headlines Cancer protein 'can be disarmed'. BBC News, November 12 2009 Links To Science Moellering RE, Cornejo M, Davis TN. Direct inhibition of the NOTCH transcription factor complex. Nature 2009; 462: 182-188 (Source: NHS News Feed)

NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells

Cancer Research — Thu, 12 Nov 2009 05:08:17 +0100

Transformed cells in lymphomas usually maintain the phenotype of the postulated normal lymphocyte from which they arise. By contrast, anaplastic large cell lymphoma (ALCL) is a T-cell lymphoma with aberrant phenotype because of the defective expression of the T-cell receptor and other T-cell–specific molecules for still undetermined mechanisms. The majority of ALCL carries the translocation t(2;5) that encodes for the oncogenic tyrosine kinase NPM-ALK, fundamental for survival, proliferation, and migration of transformed T cells. Here, we show that loss of T-cell–specific molecules in ALCL cases is broader than reported previously and involves most T-cell receptor–related signaling molecules, including CD3, ZAP70, LAT, and SLP76. We further show that NPM-ALK, but not the ...

Targeted Disruption of the S1P2 Sphingosine 1-Phosphate Receptor Gene Leads to Diffuse Large B-Cell Lymphoma Formation

Cancer Research — Thu, 12 Nov 2009 05:08:17 +0100

S1P2 sphingosine 1-phosphate receptor signaling can regulate proliferation, survival, morphology, and migration in many cell types in vitro. Here, we report that S1P2–/– mice develop clonal B-cell lymphomas with age, such that approximately half of the animals display this neoplasm by 1.5 to 2 years of age. Histologic, immunophenotypic, and molecular analyses revealed a uniform tumor phenotype with features of germinal center (GC)–derived diffuse large B-cell lymphoma (DLBCL). Tumor formation was preceded by increases in GC B cells and CD69+ T cells, as well as an increased formation of spontaneous GCs, suggesting that S1P2 loss may promote lymphomagenesis in part by disrupting GC B-cells homeostasis. With the sole exception of rare lung tumors, the effect of S1P2 gene di...

Combination Chemotherapy More Effective in Primary CNS Lymphoma

AccessMedicine Updates — Thu, 12 Nov 2009 03:30:01 +0100

(Source: AccessMedicine Updates)

Widespread expression of prostate apoptosis response-4 in nasopharyngeal carcinoma

Head and Neck — Thu, 12 Nov 2009 00:00:00 +0100

Prostate apoptosis response-4 (Par-4) augments apoptosis in various tumors, either during apoptotic insult or by ectopic overexpression. However, investigation of Par-4 expression in nasopharyngeal carcinoma (NPC) is lacking.Specimens from patients with NPC, hypopharyngeal carcinoma (HPC), or oral cavity cancer were examined for Par-4 expression using immunohistochemistry. NPC cell proliferation and apoptosis were analyzed using immunohistochemical staining for Ki67, B-cell lymphoma 2 (Bcl-2), and in situ terminal deoxyribonucleotidyl transferase (TdT)-mediated biotin-16-dUTP nick end-labeling (TUNEL) assay, respectively.Par-4 was ubiquitously expressed in NPC biopsies (96.2%, 25/26) and was significantly higher than in HPC (47.6%, 50/105, p < .0001) and oral cavity cancers (38.7%, 12/31, ...

Peripheral T-cell lymphoma gene expression profiling and potential therapeutic exploitations

British Journal of Haematology — Thu, 12 Nov 2009 00:00:00 +0100

In conclusion, gene expression profiling is beginning to change the pathological classification, the prognosis profiles and the therapeutic approach in T-cell lymphomas. (Source: British Journal of Haematology)

Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH) : revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma

Journal of Hematology and Oncology — Thu, 12 Nov 2009 00:00:00 +0100

Conclusions: To the best of our knowledge, the current study represents the first genomic exploration of PL. The genomic aberration pattern of PL appears to be more similar to that of DLBCL (AIDS-related or non AIDS-related) than to PCM. Our findings suggest that PL may remain best classified as a subtype of DLBCL at least at the genome level. (Source: Journal of Hematology and Oncology)

Activity of Thalidomide and Lenalidomide in Mantle Cell Lymphoma.

Acta Haematologica — Thu, 12 Nov 2009 00:00:00 +0100

In conclusion, our data support a role for immunomodulatory drugs in the treatment of MCL. PMID: 19907157 [PubMed - as supplied by publisher] (Source: Acta Haematologica)

Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin

Journal of Cellular Biochemistry — Thu, 12 Nov 2009 00:00:00 +0100

Suberoylanilide hydroxamic acid (SAHA) is an inhibitor of histone deacetylases (HDACs) which is being introduced into clinic for the treatment of hematological diseases. We studied the effect of this compound on six human hematopoietic cell lines (JURL-MK1, K562, CML-T1, Karpas-299, HL-60, and ML-2) as well as on normal human lymphocytes and on leukemic primary cells. SAHA induced dose-dependent and cell type-dependent cell death which displayed apoptotic features (caspase-3 activation and apoptotic DNA fragmentation) in most cell types including the normal lymphocytes. At subtoxic concentrations (0.5-1 µM), SAHA increased the cell adhesivity to fibronectin (FN) in all leukemia/lymphoma-derived cell lines but not in normal lymphocytes. This increase was accompanied by an enhanced expressi...

Activity of Thalidomide and Lenalidomide in Mantle Cell Lymphoma

Karger Publishers — Wed, 11 Nov 2009 23:00:00 +0100

Acta Haematol 2010;123:21-29 (DOI:10.1159/000257990) (Source: Karger Publishers)

A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation

Cancer Immunology, Immunotherapy — Wed, 11 Nov 2009 19:20:13 +0100

Abstract Epstein–Barr virus (EBV)-related malignancies such as post-transplant lymphoproliferative disease (PTLD) are severe complications after allogeneic stem cell transplantation and solid-organ transplantation. In immunosuppressed transplant recipients, the activity of EBV-specific CTLs are often decreased or absent which leads to an increased risk of developing PTLD. If primary treatment modalities of PTLD fail, the most efficient way of treating the malignancy is adopting EBV-specific CTLs from the donor or, more recently, third-party donors. However, both are time consuming and expensive and often it is too late to administer cells to the patient. We have for the first time, using a rapid isolation protocol of EBV-specific T cells, treated and cured a patient suff...

Zinc and Selenium Status in Pediatric Malignant Lymphomas

Nutrition and Cancer — Wed, 11 Nov 2009 13:49:21 +0100

(Source: Nutrition and Cancer)

Immunoelectron microscopy in mycosis fungoides and benign dermatoses. Expression of CD3, CD4 and CD7 receptors.

Neoplasma — Wed, 11 Nov 2009 11:46:23 +0100

Authors: Grzanka AA, Placek W, Grzanka A, Sokolowska-Wojdylo M, Zuryn A Mycosis fungoides is an epidermotropic cutaneous T-cell lymphoma (CTCL).Specimens for presented study were taken from sixteen patients with MF confirmed by immunohistochemical methods and PCR and from nine patients with benign dermatoses. To demonstrate CD3, CD4 and CD7 antigens immunogold method was used. We saw morphological differences between lymphocytes from MF and benign dermatoses. In MF, CD3 and CD4 were present rather in form of clusters placed on the surface of cell. On the contrary -CD3 to CD7 distribution analysis showed that these antigens were present rather individually, however there were seen clusters as well. In MF tumor stage labelling decreased in following order: CD7, CD3 and CD4. We also found...

FDA Approved Leukemia Drug Shows Promising Activity In Ovarian Cancer Cells

Health News from Medical News Today — Wed, 11 Nov 2009 09:00:00 +0100

The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. (Source: Health News from Medical News Today)

FDA Approved Leukemia Drug Shows Promising Activity In Ovarian Cancer Cells

Lymphoma / Leukemia News From Medical News Today — Wed, 11 Nov 2009 09:00:00 +0100

ChemGenex Announces FDA Accepts NDA For Omapro™ (Omacetaxine Mepesuccinate) And Grants The Filing Priority Review Status

Health News from Medical News Today — Wed, 11 Nov 2009 06:00:00 +0100

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the U.S. Food & Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation. (Source: Health News from Medical News Today)

ChemGenex Announces FDA Accepts NDA For Omapro™ (Omacetaxine Mepesuccinate) And Grants The Filing Priority Review Status

Cancer / Oncology News From Medical News Today — Wed, 11 Nov 2009 06:00:00 +0100

NCCN Receives Research Grant To Evaluate Pralatrexate In Solid Tumors And Hematologic Malignancies

Cancercompass News: Colorectal Cancer — Wed, 11 Nov 2009 00:00:00 +0100

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding. (Source: Cancercompass News: Colorectal Cancer)

2010 ASN Abstracts

Journal of Neuroimaging — Wed, 11 Nov 2009 00:00:00 +0100

Conclusion: VBD can enlarge to significant dimensions, producing compressive symptoms in the brainstem, as well as thrombosis and ischemic strokes. SACE of the dolichoectasia can be effective for the vessel reconstruction, to prevent progression of the dilatation, and other potential clinical events. 3. Three Case Reports of Multiple Carotid and/or Vertebral Artery Dissections in Female Mei Lu, Heather Gornik, Esteban Cheng Ching, Vikram Kashyap, Rishi Gupta Cleveland Clinic Foundation, Cleveland, OH 44195, United States Introduction: Multiple carotid and/or vertebral artery dissections are rare. However, patients with multiple dissections can suffer from severe stroke, leading to significant mobility and mortality. The etiology underlying the bilateral carotid dissection is not clear. The...

Erythropoiesis-stimulating agents: concern over patterns of use in the US and risks

NeLM - Renal medicine — Wed, 11 Nov 2009 00:00:00 +0100

Source: J Nat Cancer Inst Area: News According to research published early online in the Journal of the National Cancer Institute, use of erythropoiesis-stimulating agents in US cancer patients undergoing chemotherapy has increased 10-fold since their introduction, yet there has been no associated decline in the rate of blood transfusions. Researchers sought to evaluate the impact of erythropoiesis-stimulating agents on the blood transfusion rate, long-term risk of venous thromboembolism, and overall survival in patients who were aged 65 years or older, who had a pathologically confirmed primary diagnosis of diffuse large B-cell lymphoma, in the 10 years after these agents were approved by the US FDA. The main outcomes of the study were receipt of blood transfusion and diagnost...

The Effect of Microenvironmental CD40 Signals on TRAIL- and Drug-induced Apoptosis in Follicular Lymphoma Cells

Scandinavian Journal of Immunology — Wed, 11 Nov 2009 00:00:00 +0100

Follicular lymphoma (FL) cells are malignant counterparts of germinal centre (GC) B cells. Microenvironment of FL B cells has an important role in the progression of FL and might also have an impact on the treatment of FL. CD40 is an important mediator of microenvironmental survival signals in GCs. Here we studied responses of CD40 signalling on TRAIL-, dexamethasone- and doxorubicin-induced apoptosis in three human FL cell lines. In two of the FL cell lines, CD40 protected cells from apoptosis which was entirely dependent on the activation of NF-[kappa]B. In one of the FL cell lines, CD40 induced apoptosis itself. However, inhibition of NF-[kappa]B induced apoptosis in all three FL cell lines. Therefore, our results indicate that inhibitors of NF-[kappa]B or critical downstream anti-apopt...

Apoptosis Induction in Human Leukemic Cells by a Novel Protein Bengalin, Isolated from Indian Black Scorpion Venom: through Mitochondrial Pathway and Inhibition of Heat Shock Proteins.

Chemico-Biological Interactions — Wed, 11 Nov 2009 00:00:00 +0100

Authors: Gupta SD, Gomes A, Debnath A, Saha A, Gomes A Scorpion venom possesses protein toxins having numerous biological activities, some of which are potentially anticancerous. Previously we had reported antiproliferative activity of the venom of Indian black scorpion, Heterometrus bengalensis Koch. Here we have isolated and purified a novel protein named Bengalin (72kD) from the venom, responsible for antiproliferative and apoptogenic activities against human leukemic cells U937 (histiocytic lymphoma) and K562 (chronic myelogenous leukemia). N-terminal sequence of first 20 amino acids of Bengalin was G-P-L-T-I-L-H-I-N-D-V-H-A-A/R-F-E-Q/G-F/G-N-T. Bengalin induced cell growth inhibition at IC(50) values of 3.7mug/ml and 4.1mug/ml for U937 and K562 cells respectively did not significa...

High-Dose Cytarabine Plus High-Dose Methotrexate Versus High-Dose Methotrexate Alone in Patients With Primary CNS Lymphoma: A Randomised Phase 2 Trial

OncologySTAT Journal Scans — Tue, 10 Nov 2009 13:49:13 +0100

The complete remission rate was 46% with high-dose cytarabine plus high-dose methotrexate compared with 18% for high-dose methotrexate alone in patients with in CNS lymphoma. Background: Chemotherapy... (Source: OncologySTAT Journal Scans)

FDA Approves Romidepsin for the Treatment of Cutaneous T-Cell Lymphoma

OncologySTAT Latest News — Tue, 10 Nov 2009 13:49:12 +0100

Romidepsin for injection has been approved for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least 1 prior systemic therapy. The US Food and Drug Administration granted... (Source: OncologySTAT Latest News)

Targeting PKC-theta Protein: A Way To Inhibit Harmful Immune Responses?

Health News from Medical News Today — Tue, 10 Nov 2009 13:00:00 +0100

Targeting PKC-theta Protein: A Way To Inhibit Harmful Immune Responses?

Immune System / Vaccines News From Medical News Today — Tue, 10 Nov 2009 13:00:00 +0100

For some individuals with leukemia, the best treatment option is to receive a bone marrow transplant from a person who is not an identical genetic match. The donor bone marrow gives rise to immune cells that attack the leukemia (a response known as a graft-versus leukemia [GVL] response). In some cases, however, the immune cells generated by the donor bone marrow attack other cells in the patient's body and this highly toxic response is known as graft-versus-host disease (GVHD). (Source: Immune System / Vaccines News From Medical News Today)

Rasburicase Approved to Manage Complications of Anticancer Therapy

Cancer Network — Tue, 10 Nov 2009 12:00:00 +0100

Sanofi-aventis US announced that the US Food and Drug Administration (FDA) has granted marketing approval for rasburicase (Elitek) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid. (Source: Cancer Network)

FDA Approves Drug Treatment For Rare Cancer

Health News from Medical News Today — Tue, 10 Nov 2009 11:00:00 +0100

The U.S. Food and Drug Administration has approved Istodax (romidepsin), an injectable medication, for treatment of patients with a rare form of cancer known as Cutaneous T-cell Lymphoma (CTCL). Cutaneous T-cell lymphoma is a slow-growing cancer of infection-fighting white blood cells called T-lymphocytes. Most cases start with dry skin, red rash, and itching that can become severe. (Source: Health News from Medical News Today)

FDA Approves Drug Treatment For Rare Cancer

Cancer / Oncology News From Medical News Today — Tue, 10 Nov 2009 11:00:00 +0100

EpiCept Corporation Announces Health Canada Accepts Ceplene(R) Application For Review

Health News from Medical News Today — Tue, 10 Nov 2009 08:00:00 +0100

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission. (Source: Health News from Medical News Today)

EpiCept Corporation Announces Health Canada Accepts Ceplene(R) Application For Review

Lymphoma / Leukemia News From Medical News Today — Tue, 10 Nov 2009 08:00:00 +0100

Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG

International Journal of Cancer — Tue, 10 Nov 2009 00:00:00 +0100

MicroRNA-153 (miR-153) is a brain-specific miRNA that is expressed at a significantly lower level in glioblastoma (GBM) relative to non-neoplastic brain tissue. Although the expression pattern of miR-153 has been extensively established, its target genes and cellular mechanism remain undefined. To investigate into the potential function of miR-153 in glioblastmas, we transfected a GBM cell line DBTRG-05MG with synthetic miR-153 oligos and observed decreased cell proliferation and increased apoptosis. Bioinformatics analysis revealed that anti-apoptosis family member B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1) are potential targets of miR-153. Indeed, Western blot analysis indicated that miR-153 downregulated both Bcl-2 and Mcl-1 at the protein levels. Single stra...

NCCN Receives Research Grant to Evaluate Pralatrexate in Solid Tumors and Hematologic Malignancies

National Comprehensive Cancer Network Oncology Research Program — Tue, 10 Nov 2009 00:00:00 +0100

Istodax Approved for Cutaneous T-Cell Lymphoma

Modern Medicine — Tue, 10 Nov 2009 00:00:00 +0100

(Source: Modern Medicine)

Targeted Disruption of the S1P2 Sphingosine 1-Phosphate Receptor Gene Leads to Diffuse Large B-Cell Lymphoma Formation.

Cell Research — Tue, 10 Nov 2009 00:00:00 +0100

Authors: Cattoretti G, Mandelbaum J, Lee N, Chaves AH, Mahler AM, Chadburn A, Dalla-Favera R, Pasqualucci L, Maclennan AJ S1P(2) sphingosine 1-phosphate receptor signaling can regulate proliferation, survival, morphology, and migration in many cell types in vitro. Here, we report that S1P(2)(-/-) mice develop clonal B-cell lymphomas with age, such that approximately half of the animals display this neoplasm by 1.5 to 2 years of age. Histologic, immunophenotypic, and molecular analyses revealed a uniform tumor phenotype with features of germinal center (GC)-derived diffuse large B-cell lymphoma (DLBCL). Tumor formation was preceded by increases in GC B cells and CD69(+) T cells, as well as an increased formation of spontaneous GCs, suggesting that S1P(2) loss may promote lymphomagenesis...

Association Between Exposure to Topical Tacrolimus or Pimecrolimus and Cancers(December).

The Annals of Pharmacotherapy — Tue, 10 Nov 2009 00:00:00 +0100

CONCLUSIONS: Exposure to topical tacrolimus or pimecrolimus was not associated with an increase in the overall cancer rate. Use of topical tacrolimus may be associated with an increased risk of T-cell lymphoma. PMID: 19903860 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)

TCRgamma gene rearrangement in cutaneous T-cell lymphoma: comparative study of PCR with denaturing gradient gel electrophoresis and GeneScan analysis.

The British Journal of Dermatology — Tue, 10 Nov 2009 00:00:00 +0100

Conclusions BIOMED-2-GS analysis of the TCRgamma gene is as sensitive and specific as DGGE for CTCL diagnosis. In addition, BIOMED-2-GS is less time-consuming and gives more information concerning the size and nature of TCR-GR. PMID: 19906072 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)

Primary cutaneous B-cell lymphoma is associated with somatically hypermutated immunoglobulin variable genes and frequent use of VH1-69 and VH4-59 segments.

The British Journal of Dermatology — Tue, 10 Nov 2009 00:00:00 +0100

Conclusion Data indicate that neoplastic B cells of PBCBL have experienced the germinal-center reaction and also suggest that the involvement of VH genes is not entirely random in PCBCL and that common antigen epitopes could be pathologically relevant in cutaneous lymphomagenesis. PMID: 19906071 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)

FDA Approves Drug Treatment for Rare Cancer

Food and Drug Administration — Mon, 09 Nov 2009 21:01:00 +0100

Cutaneous T-cell lymphoma affects about 1,500 Americans annually The U.S. Food and Drug Administration has approved Istodax (romidepsin), an injectable medication, for treatment of patients with a rare form of cancer known as Cutaneous T-cell Lymphoma (CTCL). (Source: Food and Drug Administration)

Rapid Optic Nerve Infiltration by Diffuse Large B-Cell Lymphoma [Ophthalmic Images]

Archives of Opthalmology — Mon, 09 Nov 2009 20:51:48 +0100

(Source: Archives of Opthalmology)

Approved Lymphoma Drug Shows Promise In Early Tests Against Bone Cancer

ScienceDaily Headlines — Mon, 09 Nov 2009 07:00:00 +0100

A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study. (Source: ScienceDaily Headlines)

Istodax Approved for Cutaneous T-Cell Lymphoma

MedicineNet Cancer General — Mon, 09 Nov 2009 07:00:00 +0100

Title: Istodax Approved for Cutaneous T-Cell LymphomaCategory: Health NewsCreated: 11/6/2009 4:10:00 PMLast Editorial Review: 11/9/2009 (Source: MedicineNet Cancer General)

Acute dystonic reactions in a lady presenting with repetitive involuntary muscle twitching: a case report

BioMed Central — Mon, 09 Nov 2009 00:00:00 +0100

A 56-year-old lady was admitted with complaint of involuntary muscle twitching around the eyes, face and neck for two days. She had a history of low grade non-hodgkin lymphoma with completion of the first cycle of chemotherapy. Her medication on presenting consisted of Ondansetron 8 mg two times a day and Metoclopramide 10 mg three times a day (TDS). She started taking these medications 24 hours before having the above symptoms. She was clinically diagnosed with acute dystonic reactions and was also secondarily treated with anti-emetic medications. She was given IV procyclidine 10 mg stat followed by per oral (PO) procyclidine 2.5 mg TDS. Within an hour of administering IV procyclidine her symptoms began to gradually settle down.Acute dystonic reactions are not a very rare clinical present...

Extragenital lichen sclerosus et atrophicus mimicking cutaneous T-cell lymphoma: report of a case

Journal of Cutaneous Pathology — Mon, 09 Nov 2009 00:00:00 +0100

We report a case of extragenital LSA in which both histological patterns were present in the same clinically homogenous and stable lesion. A 27-year-old man presented with a history of white atrophic plaques on the trunk. A biopsy of an abdominal lesion revealed epidermal thinning, a superficial perivascular lymphoid cell infiltrate with focal epidermotropism, mild nuclear atypia and perinuclear halos. Immunophenotyping showed decreased CD5 and CD7, with a slight predominance of CD8-positive T-lymphocytes. All these changes were suggestive of MF. However, a repeat biopsy 3 months later from the same stable plaque revealed features diagnostic of LSA. LSA mimicking early MF histologically has been reported in genital skin. Conversely, MF may clinically and histopathologically resemble LSA. W...

Cutaneous presentation of post-renal transplant lymphoproliferative disorder: a series of four cases

Journal of Cutaneous Pathology — Mon, 09 Nov 2009 00:00:00 +0100

We report detailed histological and molecular characteristics of four post transplant lymphoproliferative disorders (PTLD) presenting in the skin of renal transplant patients, and their clinical outcome. Three had B-cell lymphomas (cases 1[ndash]3), and one had a T-cell lymphoma (case 4). All B-cell lymphomas showed Epstein-Barr virus (EBV) by immunohistochemistry (IHC) or in situ hybridization (ISH). Cases 1 and 2 were large cell lymphomas, and case 3 a plasmacytoma. Case 1 showed light chain restriction and heavy chain gene rearrangement by polymerase chain reaction (PCR). The patient was then diagnosed with an abdominal lymphoma and died of sepsis. Case 2 had no recoverable DNA. Case 3 had a plasmacytoma that showed monoclonal light chain restriction on IHC and an oligoclonal heavy chai...

FDA approves romidepsin (Istodax®) for treatment of cutaneous T-cell lymphoma

NeLM - Oncology — Mon, 09 Nov 2009 00:00:00 +0100

Source: BioSpace Area: News The FDA has approved romidepsin (Istodax®), a histone deacetylase (HDAC) inhibitor, for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. CTCL is a type of non-Hodgkin's lymphoma, but caused by a mutation of T cells, unlike most non-Hodgkin's lymphomas which are generally of B-cell origin. Approval was based upon two prospective multicentre, single-arm clinical studies in 167 patients, which reported overall objective disease response rates (primary efficacy endpoint) of 34% and 35%. The most common adverse reactions reported in the two studies were nausea, fatigue, infections, vomiting, anorexia, anaemia, thrombocytopenia, ECG T-wave changes, neutropenia and lymphopenia. (Source: NeLM - Oncolo...

Cutaneous T-cell lymphoma (mycosis fungoides) relapsed with different immunological phenotype after bone marrow transplant

British Journal of Dermatology — Mon, 09 Nov 2009 00:00:00 +0100

(Source: British Journal of Dermatology)

Cutaneous T-cell lymphoma (mycosis fungoides) relapsed with different immunological phenotype after bone marrow transplant.

The British Journal of Dermatology — Mon, 09 Nov 2009 00:00:00 +0100

Authors: Okada S, Nannya Y, Ota S, Takazawa Y, Yamamoto G, Kumano K, Izutsu K, Takahashi T, Chiba S, Kurokawa M PMID: 19903173 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)

[Guideline for radioimmunotherapy of CD20+ follicular B-cell non-Hodgkin s lymphoma.]

Nuklearmedizin — Mon, 09 Nov 2009 00:00:00 +0100

Authors: Fischer M, Grünwald F, Knapp WH, Trümper L, von Schilling C, Dreyling M This guideline is a prerequisite for the quality management in the treatment of non-Hodgkon- lymphomas in patients with relapsed or refractory follicular lymphoma after rituximab therapy and as consolidation therapy after first remission following CHOP like treatment using radioimmunotherapy. It is based on an interdisciplinary consensus and contains background information and definitions as well as specified indications and detailed contraindications of treatment. Essential topics are the requirements for institutions performing the therapy. For instance, presence of an expert for medical physics, intense cooperation with all colleagues committed to treatment of lymphomas, and a certificate of i...

A rare case of primary pancreatic Burkitt lymphoma in a young Indian male. Case report and review of the literature.

JOP — Sun, 08 Nov 2009 02:04:02 +0100

CONCLUSION: Early diagnosis of this aggressive tumor and prompt induction of chemotherapy dramatically improved the patient's condition and avoided unnecessary surgical intervention. PMID: 19890195 [PubMed - in process] (Source: JOP)

An interesting diagnosis for a presacral mass: Case report

International Seminars in Surgical Oncology — Sun, 08 Nov 2009 00:00:00 +0100

We present an unusual cause of a presacral mass being extramedullary haematopoiesis, found incidentally in a 71 year old female. Extramedullary haematopoiesis is defined as the production of myeloid and erythroid elements outside of the bone-marrow. This diagnosis is extremely rare in the presacral area especially in a patient with no haematological abnormalities. A review of the literature is presented. (Source: International Seminars in Surgical Oncology)

Musculoskeletal manifestations in patients with malignant disease

Clinical Rheumatology — Sat, 07 Nov 2009 19:13:27 +0100

Abstract To detect and describe the incidence of musculoskeletal manifestations in different malignant diseases as well as their relation to the treatment received whether by chemotherapy or radiation therapy. Sixty patients with different malignant diseases were included in this study, 45 with solid tumors and 15 patients with hematological malignancy. The mean age was 46.55 ± 11.04 years and the mean disease duration was 2 ± 0.75 years. The patients were fully examined for any rheumatologic involvement, laboratory investigations were performed as well as dual energy X-ray absorptiometry study for bone densitometry. Treatment strategies were assessed including the chemotherapeutics, radiation therapy, and/or surgery. Myalgias and arthralgias were the mo...

Exercise Is Good Medicine For Lymphoma Patients

ScienceDaily Headlines — Sat, 07 Nov 2009 10:00:00 +0100

A healthy dose of exercise is good medicine, even for lymphoma patients receiving chemotherapy, University of Alberta researchers have found. (Source: ScienceDaily Headlines)

Advanced Leukemia Successfully Treated With First Use Of Antibody And Stem Cell Transplantation

Health News from Medical News Today — Sat, 07 Nov 2009 08:00:00 +0100

For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. (Source: Health News from Medical News Today)

Advanced Leukemia Successfully Treated With First Use Of Antibody And Stem Cell Transplantation

Lymphoma / Leukemia News From Medical News Today — Sat, 07 Nov 2009 08:00:00 +0100

ERYtech Pharma Starts Its Pivotal Clinical Trial For GRASPA(R) In Acute Lymphoblastic Leukaemia

Health News from Medical News Today — Sat, 07 Nov 2009 05:00:00 +0100

ERYtech Pharma announces the start of its pivotal clinical trial for GRASPA®, its lead product in Acute Lymphoblastic Leukaemia. This phase III trial has begun in France and will be enlarged to a European scale. Up to 80 patients with relapsed Acute Lymphoblastic Leukaemia, aged from 1 to 55 years old will be enrolled. (Source: Health News from Medical News Today)

ERYtech Pharma Starts Its Pivotal Clinical Trial For GRASPA(R) In Acute Lymphoblastic Leukaemia

Cancer / Oncology News From Medical News Today — Sat, 07 Nov 2009 05:00:00 +0100

A systems biology view of cancer.

Biochimica et Biophysica Acta — Sat, 07 Nov 2009 04:26:32 +0100

Authors: Laubenbacher R, Hower V, Jarrah A, Torti SV, Shulaev V, Mendes P, Torti FM, Akman S In order to understand how a cancer cell is functionally different from a normal cell it is necessary to assess the complex network of pathways involving gene regulation, signaling, and cell metabolism, and the alterations in its dynamics caused by the several different types of mutations leading to malignancy. Since the network is typically complex, with multiple connections between pathways and important feedback loops, it is crucial to represent it in the form of a computational model that can be used for a rigorous analysis. This is the approach of systems biology, made possible by new -omics data generation technologies. The goal of this review is to illustrate this approach and its utilit...

FDA Approves Gloucester Pharmaceuticals' ISTODAX(R) For Patients With Cutaneous T-cell Lymphoma

Health News from Medical News Today — Sat, 07 Nov 2009 00:00:00 +0100

FDA Approves Gloucester Pharmaceuticals' ISTODAX(R) For Patients With Cutaneous T-cell Lymphoma

Cancer / Oncology News From Medical News Today — Sat, 07 Nov 2009 00:00:00 +0100

Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. The approval of ISTODAX was based on objective disease response defined as the proportion of patients with confirmed complete response or partial response. (Source: Cancer / Oncology News From Medical News Today)

Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy

Cancer — Sat, 07 Nov 2009 00:00:00 +0100

The objective of the current study was to determine the prevalence of past HBV infection in patients with lymphoma and its relevance in terms of HBV-related complications.The authors reviewed 430 patients with lymphoma from May 2006 to May 2008.Among the 430 patients, 233 had both the HBsAg and HBcAb tests performed, whereas 197 had only the HBsAg test performed. Among those with both tests performed, 34.3% (80 of 233) were HBcAb positive only. Of these 80 patients, 58 had a concomitant HBV DNA level test, which was positive in 3 (5.2%). Of the 67 patients with past and 26 with chronic HBV infection who received chemotherapy, HBV reactivation occurred in 1.5% and 42.3% of patients, respectively (P (Source: Cancer)

Appropriate timing of G-CSF use after mobilization chemotherapy significantly increases the yield of CD34+ cells in autoPBSCT

Journal of Clinical Apheresis — Sat, 07 Nov 2009 00:00:00 +0100

The yield of CD34+ cells collected by apheresis for autologous peripheral blood stem cell (PBSC) transplantation was greatly increased when the appropriate timing was determined to begin using G-CSF after COAEP (Cytoxan, Vinblastine, Arabinosylcytosin, Etoposide and Prednisone) mobilization. Twenty-nine patients with lymphoma or multiple myeloma (MM) received the same mobilization chemotherapy, including cytoxan (CTX) 400 mg/m2 d1; vinblastine (VLB) 2 mg/m2 d1; Ara-C 60 mg/m2 × 5d; vp-16 60 mg/m2 × 5d; and prednisone 40 mg/m2 × 5d. The historical control group (12 cases) received subcutaneous G-CSF (filgrastim) at the first restoration after the initial nadir of the peripheral WBC count. The experimental group (17 cases) received G-CSF during the steady rise of the WBC count (end of flu...

The geoepidemiology of Sjögren's syndrome.

Autoimmunity Reviews — Sat, 07 Nov 2009 00:00:00 +0100

The geoepidemiology of Sjögren's syndrome. Autoimmun Rev. 2009 Nov 7; Authors: Mavragani CP, Moutsopoulos HM Sjogren's syndrome (SS) is a slowly progressing autoimmune disease, affecting predominantly middle-aged women, with a female to male ratio reaching 9:1. It is characterized by lymphocytic infiltration of the exocrine glands, mainly the lacrimal and salivary glands, resulting in reduced secretory functions and oral and ocular dryness. The syndrome can present alone as primary SS (pSS) or in the context of underlying connective tissue disease as secondary SS (sSS). While the pathogenesis of the disease remains elusive, environmental, genetic and hormonal contributors seem to be involved. Over the last years, compelling evidence has suggested a pivotal role of the epit...

Synchronous Advanced Pure Seminoma and Diffuse Large B-Cell Lymphoma: A Case of Multiple Oncologic Dilemmas [DIAGNOSIS IN ONCOLOGY]

Journal of Clinical Oncology — Fri, 06 Nov 2009 23:02:20 +0100

(Source: Journal of Clinical Oncology)

Coexistence of Leishmaniasis and Hodgkin's Lymphoma in a Lymph Node [DIAGNOSIS IN ONCOLOGY]

Journal of Clinical Oncology — Fri, 06 Nov 2009 23:02:20 +0100

(Source: Journal of Clinical Oncology)

Time to Treatment Does Not Influence Overall Survival in Newly Diagnosed Mantle-Cell Lymphoma [CORRESPONDENCE]

Journal of Clinical Oncology — Fri, 06 Nov 2009 23:02:20 +0100

(Source: Journal of Clinical Oncology)

Histone Deacetylase Inhibitors in Cancer Therapy [REVIEW ARTICLE]

Journal of Clinical Oncology — Fri, 06 Nov 2009 23:02:20 +0100

Conclusion HDAC inhibitors are an important emerging therapy with single-agent activity against multiple cancers, and have significant potential in combination use. (Source: Journal of Clinical Oncology)

Survival Disparities in Patients With Lymphoma According to Place of Residence and Treatment Provider: A Population-Based Study [Hematologic Malignancies]

Journal of Clinical Oncology — Fri, 06 Nov 2009 23:02:19 +0100

Conclusion Survival outcomes of patients with lymphoma may be associated with place of residence and treatment provider. High-risk patients from rural areas may benefit from better coordination of care. (Source: Journal of Clinical Oncology)